US FDA staff raise concerns over data from J&J, Bristol's CAR-T therapies

Regulatory approval for the therapies as earlier treatments could expand their use to a larger subset of blood cancer patients who are less sick than those treated with multiple therapies. The therapies - J&J's Carvykti and Bristol's Abecma - belong to class known as CAR-T.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/oIwxTan
via